Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials

Berlin, Germany and Shanghai, China – 23 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. ¹⁷⁷Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-177.

Ablaze is currently developing several Lutetium-based drug products for targeted radiotherapy (TRT). In the TRT approach, a radioisotope such as lutetium-177 is combined with tumor-specific drugs, which then deliver the radiating element of the radioisotope into tumor cells to destroy them, while largely sparing surrounding healthy tissue.

"We are excited to support the development of Ablaze’s innovative radiopharmaceuticals by providing our high-quality Lutetium-177,” stated Jutta Ludwig, Member of the Executive Board of Eckert & Ziegler and responsible for the Asia Business. “With this agreement, we are further strengthening our position on the Chinese market. Starting with clinical trial supply, we jointly aim to establish a long-term collaboration that includes supply for commercial products as well as future developments.”

"Our goal to improve the availability of TRT products in China and to make them accessible to Chinese patients requires strong and reliable partners,” said Dr Alex Qiao, Co-Founder, President and CEO of Ablaze. "We are excited about the partnership with an expert like Eckert & Ziegler who is able to guarantee the quality and security of supply we need to drive our activities forward.”

Apart from Lutetium-177, Eckert & Ziegler supplies international pharmaceutical companies with Gallium-68, Yttrium-90, Actinium-225 and other radioisotopes that are crucial for use in diagnostics and therapy.

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with more than 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the SDAX index of Deutsche Börse.
Contributing to saving lives.

About Ablaze Pharmaceuticals
Ablaze Pharmaceuticals is a clinical-stage pharmaceutical company with a mission to bring advanced targeted radiopharmaceutical therapies (TRT) to benefit cancer patients in China. Since its inception, Ablaze has secured a partnership with RayzeBio, Inc., an innovative radiopharmaceutical company based in San Diego CA, to gain exclusive development and commercial right to a series of RayzeBio’s products in the greater China region. Leveraging its team’s extensive business experience and network in cross-border product development and deal making, Ablaze strives to become the leader and the partner of choice in the emerging TRT market in China by working with strategic business partners in both China and abroad. For more information, please visit www.ablazepharma.com.Contact
Eckert & Ziegler AG
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de / jan.schoepflin@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com

Ablaze Pharmaceuticals (Shanghai) Co.,Ltd
Unit 01-02, 17F, New Bund Center, 555 West Haiyang Road, Pudong New Area, Shanghai, China
Tel.: +86 (21) 61650788
www.ablazepharma.com